On September 29, 2026, Freyya Inc., a women's pelvic-health device company based in San Antonio and Salt Lake City, announced the oversubscribed close of its pre-seed round. Alamo Angels, Texas's largest network of accredited angel investors, led the round. The amount was not disclosed. Femtech Insider covered the raise on October 5. Freyya says the money will fund its U.S. Food and Drug Administration submission and its path to commercial launch.

Why It Matters

Pelvic-floor tech has mostly meant Kegel trainers such as Elvie, Perifit and kGoal, which measure squeeze strength while the user lies still. Freyya is betting on **continuous measurement during real activity**: coughing, lifting, running. This follows the emerging science Afterglow covered in September (*Squeeze Play: The Science Says Kegels Aren't the Answer for Every Pelvic Floor*), which found that simple strengthening helps some women but not others, and that pressure management matters. For postpartum and menopausal users, pelvic floor function is closely tied to sexual function (pain, sensation, arousal and leakage during sex). A device that produces clinical-grade data could connect to the pelvic-health clinics and sexual-medicine providers that consumer Kegel apps have struggled to win over. The money is small and the regulatory path is the real hurdle. Freyya hasn't said which FDA pathway it will use, and a pre-seed round only stretches so far if the agency asks for more data. The category's recent history is a warning: Elvie's maker went into administration before Willow bought it. As Dealroom notes, women's-health funding remains uneven, and investors are backing repeat founders with exits, as here, more readily than first-timers. Watch for the ERICA data to be published, and for Freyya to say whether it is aiming at clinicians, insurers or consumers.

Femtech Insider describes the product as a tampon-inspired device. It uses biosensors to monitor intra-abdominal pressure and pelvic floor muscle force continuously, and turns those readings into data on function, symptoms and treatment plans. Freyya says it has finished building the product and completed clinical testing, including its ERICA clinical study at the University of Utah, and has hired a contract manufacturer for commercial-scale production. CEO and co-founder Dr. Gabriele "Gabi" Niederauer said the device "demonstrated outstanding comfort, retention, and precision biomechanical insights during diverse activities." Freyya's own release notes that the device is not yet FDA-cleared or CE-marked and cannot be sold in the US or Europe.

Founder track record was part of the pitch. Alamo Angels previously backed Niederauer's Bluegrass Vascular Technologies, which exited in 2023. "Gabi is the kind of founder we want to back: experienced, highly technical, and focused on solving a meaningful clinical problem," said Alamo Angels managing partner Sebastian Garzon. Board member and angel investor Lara August said the device could "turn that information into data-backed plans for women recovering after childbirth, injury, or hormonal changes." Femtech Insider cites estimates that one in four women experience pelvic floor dysfunction in their lifetime, with related healthcare costs above $20 billion a year.

Sources

Update — 2026-10-07

Initial entry — story first created.